Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19
Essy Mozaffari(Gilead Sciences (United States)), André C. Kalil(Nebraska Medical Center), Chidinma Chima-Melton, Alpesh Amin(University of California, Irvine), Tobias Welte(Medizinische Hochschule Hannover), Thomas F Oppelt(Gilead Sciences (United States)), Aastha Chandak(University of Nebraska Medical Center), Jason F. Okulicz(Gilead Sciences (United States)), Paul E. Sax(Brigham and Women's Hospital), Mark Berry(Gilead Sciences (United States)), Robert Gottlieb(Baylor University Medical Center)
Cited by 15
Related Papers
Clinical and economic burden of community-acquired pneumonia among adults in Europe
|Thorax|2010|1.1k
Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study
|The Lancet Respiratory Medicine|2020|864
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
|JAMA|2013|797
Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy
|Clinical Infectious Diseases|2001|680